First KRAS lung cancer drug Lumakras released next month
By | translator Alice Kang
22.07.06 16:34:46
가나다라
0
Amgen holds a press conference to celebrate Lumakras’ release
Demonstrated effect by targeting KRAS G12C …well tolerated a benefit
Expectations increase on its extended use in combination with immunotherapies…tasks such as activated diagnostic testing and reimbursement remain
Non-small cell lung cancer patients with KRAS mutations are expected to be able to receive treatment with the targeted anticancer therapy ‘Lumakras (sotorasib)’ starting this August. Amgen announced it will actively increase diagnostic tests and pursue reimbursement listing for the drug to increase accessibility to the only KRAS-targeted therapy in Korea.
On the 6th, Amgen Korea held a press conference to celebrate the launch of Lumakras in Korea at the Plaza Hotel in Jung-gu, Seoul.
▲Myung-Ju Ahn, Professor of Hematology-Oncology at Samsung Medical Center
Lumakras was approved as the first targeted anticancer therapy to target the KRAS mutation, in February this year by the Ministry of Food and Drug Safety. Lumakras is indicated for use as second-
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)